GEN Exclusives

More »

GEN News Highlights

More »
Nov 26, 2008

Spectrum Pharmaceuticals Forms JV with Cell Therapeutics to Jointly Market Oncology Drug

  • Spectrum Pharmaceuticals and Cell Therapeutics (CTI) will form a 50/50 owned joint venture (JV), RIT Oncology, to commercialize and develop Zevalin® in the U.S.

    Zevalin, a radioimmunotherapeutic (RIT), is currently marketed in the U.S. by Cell Therapeutics for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients who have rituximab-refractory follicular NHL. CTI submitted an sBLA in September to expand the label for use in first-line consolidation therapy in previously untreated patients with follicular NHL.

    Under terms of the agreement, upon the closing of the transaction both parties will equally provide for the future capital requirements of the JV and share equally in the profits and losses. Cell Therapeutics will receive an initial payment of $7.5 million at closing and $7.5 million in early January, in addition up to $15 million product sales milestone payments upon achievement of certain revenue targets.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?